Zoetis Joint Venture in China Addresses Swine Producers’ Needs with Rui Lan An Vaccine

The Zoetis joint venture in Jilin, China announced on August 27 the launch of Rui Lan An™, a specialized vaccine to help control porcine reproductive and respiratory syndrome (PRRS). The vaccine is the first to emerge from the Zoetis joint venture established to develop and manufacture vaccines specifically to meet the needs of China’s livestock producers.

“Rui Lan An represents our commitment to help assure a safe, sustainable food supply from healthy food production animals through global scientific expertise and local innovation. It is a key milestone for Zoetis’ business in China,” said Stefan Weiskopf, executive vice president and president, Asia Pacific region at Zoetis. “Our innovation starts with our customers and an understanding of their everyday animal health challenges.”

The vaccine strain was originally isolated in China, in accordance with The Food and Agriculture Organization of the United Nations’ best practices[1]. “Rui Lan An exemplifies the dedication of our joint venture to develop and manufacture quality vaccines well matched to the local health challenges facing China’s pork industry.” added Weiskopf. “Our high quality standards and the efficacy of Rui Lan An coupled with our technical services will provide producers with the support they need to protect their herds.”

Rui Lan An is manufactured at the Zoetis joint venture’s good manufacturing practices (GMP)-approved site in Jilin, China.

PPRS is one of the most economically devastating viral diseases afflicting swine farms in China, one of the largest swine industries in the world. In 2012, the nation had an annual population of 685 million pigs.

[1] The Food and Agriculture Organization of the United Nations, Porcine reproductive and respiratory syndrome (PRRS) http://www.fao.org/docrep/013/al849e/al849e00.pdf